Long-term cardiac and vascular disease outcomes following adjuvant tamoxifen therapy: Current understanding of impact on physiology and overall survival

Minerva Medica

Volumn 104, Issue 2, 2013, Pages 141-153

  Onitilo, A A ^a,b   Kar, P ^c   Engel, J M ^a   Glurich, I ^a  

^a MARSHFIELD CLINIC   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Allegiance Health ^*  (United States)

Author keywords

Breast neoplasms; Cardiovascular diseases; Heart diseases; Pulmonary embolism; Stroke; Tamoxifen; Venous thrombosis

Indexed keywords

AROMATASE INHIBITOR; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; TAMOXIFEN; TRIACYLGLYCEROL;

ADJUVANT THERAPY; BREAST CANCER; CANCER SURVIVAL; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HEART INFARCTION; HEART PROTECTION; HUMAN; LIPID ANALYSIS; LONG TERM CARE; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LIPOPROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN; THROMBOEMBOLISM;

EID: 84877348066     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-44.
2. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106.
3. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991;303:435-7.
4. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 1995;311.977-80.
5. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001;93:456-62. (Pubitemid 32266538)
6. Nordenskjöld B, Rosell J, Rutqvist LE, Malmström PO, Bergh J, Bengtsson NO et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 2005;97:1609-10. (Pubitemid 41662715)
7. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398-406 (Pubitemid 23264348)
8. Rutqvist LE, Johansson H; Stockholm Breast Cancer Study Group. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 2007;46:133-45. (Pubitemid 46277056)
9. Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997;89:747-9.
10. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62. (Pubitemid 41672231)
11. Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol 2011;29:1657-63.
12. Delozier T, Spielmann M, Macé-Lesec'h J, Janvier M, Hill C, Asselain B et al. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group. J Clin Oncol 2000;18:3507-12.
13. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012 [Epub ahead of print].
14. Estteva FJ, Hortobagyi GN. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast 2006;15:301-12. (Pubitemid 43812225)
15. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991;115:860-4.
16. Sawada S, Sato K, Kusuhara M, Ayaori M, Yonemura A, Tamaki K et al. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer. Acta Oncologica 2005;44:134-44.
17. Banerjee S, Smith IE, Folkerd L, Iqbal J, Barker P, Dowsett M et al. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann Oncol 2005;16:1632-8. (Pubitemid 41510137)
18. Morales M, Santana N, Soria A, Mosquera A, Ordovás J, Nóvoa J et al. Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer. Breast Cancer Res Treat 1996;40:265-70. (Pubitemid 26336122)
19. Cuzick J, Allen D, Baum M, Barrett J, Clark G, Kakkar V et al. Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party. Eur J Cancer 1992;29A:15-21.
20. Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995;80:3191-5.
21. Decensi A, Bonanni B, Guerrieri-Gonzaga A, Gandini S, Robertson C, Johansson H et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998;90:1461-7. (Pubitemid 28482010)
22. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996;14:429-33. (Pubitemid 26051003)
23. Vehmanen L, Saarto T, Blomqvist C, Taskinen MR, Elomaa I. Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids. Br J Cancer 2004;91:476-81. (Pubitemid 39093566)
24. Ntukidem NI, Nguyen AT, Stearns V, Rehman M, Schott A, Skaar T et al. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther 2008;83:702-10. (Pubitemid 351556014)
25. Tominaga T, Kimijima I, Kimura M, Takatsuka Y, Takashima S, Nomura Y et al. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. Jpn J Clinl Oncol 2010;40:627-33.
26. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
27. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor Am J Cardiol 1998,81:7B-12B. (Pubitemid 28113939)
28. Assman G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998;(Suppl M):M8-14.
29. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993;328:1220-5. (Pubitemid 23115700)
30. Zhao Y, Wang LM, Chaiswing L, Yen HC, Oberley TD, Lien YC et al. Tamoxifen protects against acute tumor necrosis factor alpha-induced cardiac injury via improving mitochondrial function. Free Radic Biol Med 2006;40:1234-41.
31. Romero WG, Da Silva FB, Borgo MV, Bissoli NS, Gouvea SA, Abreu GR. Tamoxifen alters the plasma concentration of molecules associated with cardiovascular risk in women with breast cancer undergoing chemotherapy. Oncologist 2012;17:499-507.
32. Chang NW, Chen FN, Wu CT, Lin CF, Chen DR. Apolipoprotein E4 allele influences the response of plasma triglyceride levels to tamoxifen in breast cancer patients. Clin Chim Acta 2009;401:144-7.
33. Wiseman H. Tamoxifen as an antioxidant and cardioprotectant. Biochem Soc Symp 1995;61:209-19.
34. Fabian CJ, Kimler BF. Chemoprevention for high-risk women: tamoxifen and beyond. Breast J 2001;7:311-20. (Pubitemid 33101636)
35. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
36. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-82. (Pubitemid 47073490)
37. Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 2003;21:3588-93. (Pubitemid 46594050)
38. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998;5:608-12. (Pubitemid 28270919)
39. Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005;111:650-6. (Pubitemid 40216494)
40. Hernandez RK, Sørensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 2009;115:4442-9.
41. Hernandez RK, Sørensen HT, Jacobsen J, Pedersen L, Lash TL. Tamoxifen treatment in Danish breast cancer patients and 5-year risk of arterial atherosclerotic events: a null association. Cancer Epidemiol Biomarkers Prev 2008;17:2509-11.
42. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937-47. (Pubitemid 37510624)
43. Monnier A. Effects of adjuvant aromatase inhibitor therapy on lipid profiles. Expert Rev Anticancer Ther 2006;6:1653-62. (Pubitemid 44883966)
44. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011;103:1299-309.
45. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008;371:29-40.